login
login
Image header Agence Europe
Europe Daily Bulletin No. 12974
EU RESPONSE TO COVID-19 / Health

EMA initiates ongoing evaluation of Pfizer-BioNTech SARS-CoV-2 vaccine tailored to one or more variants of concern

Brussels, 17/06/2022 (Agence Europe)On Wednesday 15 June, the European Medicines Agency (EMA) announced the start of the ongoing evaluation of a messenger RNA vaccine against SARS-CoV-2 developed by Pfizer-BioNTech and adapted to one or more variants of concern of SARS-CoV-2. This procedure, which precedes and accelerates the formal evaluation phase, will first focus on the manufacturing aspects of the vaccine. The EMA will then evaluate the data as soon as it is provided by Pfizer-BioNTech. The suitability of the vaccine for one or more specific variants of SARS-CoV-2 is not yet determined. The composition of the vaccine will depend on the recommendations of the World Health Organization, public health authorities and other regulatory bodies. (EV)

Contents

EXTERNAL ACTION
EU RESPONSE TO COVID-19
ECONOMY - FINANCE - BUSINESS
SOCIAL AFFAIRS
SECTORAL POLICIES
INSTITUTIONAL
NEWS BRIEFS